Some FDA-approved drugs for the treatment of solid cancers are 5-Aza that target histone deacetylase (HDAC) in metastatic non-small cell lung cancer [31] and inhibitors of EZH2, a subunit of Polycomb repressive complex in diffuse large B cell Lymphoma (DLBCL) [32]. The gene discussed is HDAC9; the disease is diffuse large B-cell lymphoma.